The updated recommendations includes disease congnition, testing methods, therapy and recent relevant clinical trials for NSCLC patients with EGFR ex20ins mutation, in order to provide better medication reference for clinical physicians. . The gene discussed is EGFR; the disease is non-small cell lung carcinoma.